Enliven Therapeutics, Inc.

ELVN

$48.87

Updated: 22/09/2026, 08:26:41

Market Cap

$3.49B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for ELVN

Company Profile

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

USD

NASDAQ

CEO: Richard A. Fair

Employees: 67

https://www.enliventherapeutics.com

Asset Summaries

Latest generated summaries for ELVN

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for ELVN.

Share price: $48.87
Market cap: $3.49B
Exchange: NASDAQ
Currency: USD
CEO: Richard A. Fair
Employees: 67
IPO date: 12/03/2020
Beta: 0.245
Last dividend: $0.00
Day range: $47.98 – $49.52
52-week range: $14.79 – $62.32
1-day performance: -1.17%
1-year performance: 230.54%
Current drawdown (1Y): -21.58%
CIK: 0001672619
CUSIP: 29337E102
ISIN: US29337E1029
Created: 07/12/2025, 03:46:06
Last update: 22/09/2026, 08:26:41

Track Enliven Therapeutics, Inc. with an AI analyst

See which prediction-market events move ELVN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to ELVN from your Railway `news_articles` table.

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

PRNewsWire • STOCK • 12/06/2026, 00:39:00

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PRNewsWire • STOCK • 11/06/2026, 18:05:00

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

Seeking Alpha • STOCK • 11/06/2026, 16:42:09

Enliven Therapeutics to Present at Upcoming Investor Conferences

PRNewsWire • STOCK • 21/05/2026, 18:05:00

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

PRNewsWire • STOCK • 12/05/2026, 11:53:00

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

The Motley Fool • STOCK • 28/03/2026, 13:26:54

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

The Motley Fool • STOCK • 01/02/2026, 01:58:20